Related Experiment Videos
Timely initiation of basal insulin.
1Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97201, USA.
The American Journal of Medicine
|March 12, 2004
Summary
Early introduction of basal insulin, combined with oral agents, offers a safer and more effective strategy for managing type 2 diabetes and preventing hyperglycemia. This approach aims to maintain optimal hemoglobin A1c levels and improve patient outcomes.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Type 2 diabetes mellitus (T2DM) management is evolving with new insulins and research.
- Understanding basal and postprandial hyperglycemia is key to treatment reassessment.
Purpose of the Study:
- To explore a revised treatment strategy for T2DM focusing on earlier insulin integration.
- To emphasize the benefits of basal insulin therapy in conjunction with oral agents.
Main Methods:
- Review of current clinical research and insulin profiles.
- Analysis of treatment intensification strategies as T2DM progresses.
- Evaluation of combination therapy approaches.
Main Results:
- Basal insulin, particularly glargine, provides a safe and simple method for supplementing oral therapy.
- Combining oral agents with basal insulin facilitates a smoother transition and reduces glycemic control loss.
- Early initiation of basal insulin can prevent sustained high hemoglobin A1c (HbA1c) levels.
Conclusions:
- Future T2DM treatment will involve earlier insulin use, intensified therapy, and routine combination treatments.
- Adding basal insulin earlier to oral therapy is a more desirable strategy than traditional late introduction.
- Treatments targeting postprandial hyperglycemia should be added to basal insulin later as disease progresses.